<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01575795</url>
  </required_header>
  <id_info>
    <org_study_id>PATRASCARDIOLOGY-10</org_study_id>
    <nct_id>NCT01575795</nct_id>
  </id_info>
  <brief_title>Standard (180mg) Versus Double (360mg) Loading Dose of Ticagrelor in Patients With ST-elevation Myocardial Infarction (STEMI), Undergoing Primary Percutaneous Coronary Intervention (PCI)</brief_title>
  <official_title>Standard (180mg) Versus Double (360mg) Loading Dose of Ticagrelor in Patients With ST-elevation Myocardial Infarction (STEMI), Undergoing Primary Percutaneous Coronary Intervention (PCI): a Multi-center Randomized Parallel Pharmacodynamic Study.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Patras</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of Patras</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a multi-center, prospective, randomized, single-blind, investigator initiated,&#xD;
      pharmacodynamic study of parallel design, performed at 3 institutions (Patras University&#xD;
      Hospital; Evangelismos Athens General Hospital; Gennimatas Athens General Hospital).&#xD;
&#xD;
      Patients with ST elevation myocardial infarction (symptom onset &lt; 12 hours), undergoing&#xD;
      primary percutaneous coronary intervention, who are antiplatelet naïve (Group A) or present&#xD;
      high residual PR (defined as PRU ≥ 208) immediately before primary percutaneous coronary&#xD;
      intervention, will be randomized after informed consent, in a 1:1 ratio to either:&#xD;
&#xD;
      Ticagrelor 180mg loading dose (LD), followed by a 90mg x2 maintenance dose (MD )starting 12±6&#xD;
      hours post LD Or Ticagrelor 360mg loading dose (LD), followed by a 90mg x2 maintenance dose&#xD;
      (MD) starting 12±6 hours post LD Platelet reactivity assessment will be performed at&#xD;
      randomization (Hour 0) and at 0.5, 1, 2, 4 hours after randomization, using the VerifyNow&#xD;
      assay, in platelet reactivity units (PRU).&#xD;
&#xD;
      Documentation of major adverse cardiac events (death, myocardial infarction, stroke, urgent&#xD;
      revascularization procedure with PCI or CABG) and bleeding (according to Bleeding Academic&#xD;
      Research Consortium criteria) will be performed until patient's discharge.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>April 2012</start_date>
  <completion_date type="Actual">February 2013</completion_date>
  <primary_completion_date type="Actual">February 2013</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>platelet reactivity at 1 hour post randomization in Group A, between the 2 treatment arms.</measure>
    <time_frame>1 hour</time_frame>
    <description>platelet reactivity at 1 hour post randomization in Group A, between the 2 treatment arms.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>1. Platelet reactivity at 1 hour post randomization in Group B, between the 2 treatment arms.</measure>
    <time_frame>1 hour</time_frame>
    <description>1. Platelet reactivity at 1 hour post randomization in Group B, between the 2 treatment arms.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>2. Platelet reactivity at 0.5 hour post randomization between the 2 treatment arms separately for Group A and B</measure>
    <time_frame>0.5 hour</time_frame>
    <description>Platelet reactivity at 0.5 hour post randomization between the 2 treatment arms separately for Group A and B</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Platelet reactivity at 2 hours post randomization between the 2 treatment arms separately for Group A and B</measure>
    <time_frame>2 hours</time_frame>
    <description>Platelet reactivity at 2 hours post randomization between the 2 treatment arms separately for Group A and B</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Platelet reactivity at 4 hours post randomization between the 2 treatment arms separately for Group A and B</measure>
    <time_frame>4 hours</time_frame>
    <description>Platelet reactivity at 4 hours post randomization between the 2 treatment arms separately for Group A and B</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>3. High on treatment platelet reactivity (HTPR) rates (≥208 PRU) at 0.5 hour post randomization between the 2 treatment arms, separately for Group A and B</measure>
    <time_frame>0.5 hour</time_frame>
    <description>High on treatment platelet reactivity (HTPR) rates (≥208 PRU) at 0.5 hour post randomization between the 2 treatment arms, separately for Group A and B</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>High on treatment platelet reactivity (HTPR) rates (≥208 PRU) at 1 hour post randomization between the 2 treatment arms, separately for Group A and B</measure>
    <time_frame>1 hour</time_frame>
    <description>High on treatment platelet reactivity (HTPR) rates (≥208 PRU) at 1 hour post randomization between the 2 treatment arms, separately for Group A and B</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>High on treatment platelet reactivity (HTPR) rates (≥208 PRU) at 2 hours post randomization between the 2 treatment arms, separately for Group A and B</measure>
    <time_frame>2 hours</time_frame>
    <description>High on treatment platelet reactivity (HTPR) rates (≥208 PRU) at 2 hours post randomization between the 2 treatment arms, separately for Group A and B</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>High on treatment platelet reactivity (HTPR) rates (≥208 PRU) at 4 hours post randomization between the 2 treatment arms, separately for Group A and B</measure>
    <time_frame>4 hours</time_frame>
    <description>High on treatment platelet reactivity (HTPR) rates (≥208 PRU) at 4 hours post randomization between the 2 treatment arms, separately for Group A and B</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Occurrence of any 5-day bleeding event (BARC Types 1-5)</measure>
    <time_frame>5 days</time_frame>
    <description>Occurrence of any 5-day bleeding event (BARC Types 1-5)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Occurrence of 5-day MACEs</measure>
    <time_frame>5 days</time_frame>
    <description>Occurrence of 5-day MACEs</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">83</enrollment>
  <condition>ST-elevation Myocardial Infarction</condition>
  <arm_group>
    <arm_group_label>Ticagrelor 180mg loading dose</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Ticagrelor 180mg loading dose</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Ticagrelor 360mg loading dose</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Ticagrelor 360mg loading dose</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ticagrelor</intervention_name>
    <description>Ticagrelor 360mg loading dose immediately pre prior percutaneous coronary intervention 360mg loading dose</description>
    <arm_group_label>Ticagrelor 360mg loading dose</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ticagrelor</intervention_name>
    <description>Ticagrelor 180mg loading dose 180mg loading dose</description>
    <arm_group_label>Ticagrelor 180mg loading dose</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Age ≥ 18 years old&#xD;
&#xD;
          2. Patients with STEMI (onset of pain &lt; 12 hours) with indication for primary PCI&#xD;
&#xD;
          3. Antiplatelet naïve or presenting HTPR (≥ 208 PRU) immediately before primary&#xD;
             percutaneous coronary intervention&#xD;
&#xD;
          4. Informed consent obtained in writing&#xD;
&#xD;
        Exclusion Criteria&#xD;
&#xD;
          -  Pregnancy&#xD;
&#xD;
          -  Breastfeeding&#xD;
&#xD;
          -  Inability to give informed consent or high likelihood of being unavailable until the&#xD;
             Day 5&#xD;
&#xD;
          -  Cardiogenic shock&#xD;
&#xD;
          -  Major periprocedural complications (death, stent thrombosis, vessel perforation,&#xD;
             arrhythmias requiring cardioversion, temporary pacemaker insertion or intravenous&#xD;
             antiarrhythmic agents, respiratory failure requiring intubation, vascular injury&#xD;
             (arteriovenous shunt, retroperitoneal bleeding), major bleeding (need for bood&#xD;
             transfusion or drop in haemoglobin post-PCI by ≥ 5 gr/ dl or intracranial bleeding).&#xD;
&#xD;
          -  Unsuccessful PCI (residual stenosis &gt; 30% or flow &lt; ΤΙΜΙ 3)&#xD;
&#xD;
          -  Known hypersensitivity to ticagrelor&#xD;
&#xD;
          -  History of gastrointestinal bleeding, genitourinary bleeding or other site abnormal&#xD;
             bleeding within the previous 3 months.&#xD;
&#xD;
          -  Other bleeding diathesis, or considered by investigator to be at high risk for&#xD;
             bleeding&#xD;
&#xD;
          -  Any previous history of stroke, intracranial hemorrhage or disease (neoplasm,&#xD;
             arteriovenous malformation, aneurysm).&#xD;
&#xD;
          -  Thrombocytopenia (&lt; 100.000/μL) at randomization&#xD;
&#xD;
          -  Anaemia (Hct &lt; 30%) at randomization&#xD;
&#xD;
          -  Polycytaemia (Hct &gt; 52%) at randomization&#xD;
&#xD;
          -  Periprocedural IIb/IIIa inhibitors administration&#xD;
&#xD;
          -  Thrombolysis administration&#xD;
&#xD;
          -  Recent (&lt; 6 weeks) major surgery or trauma, including GABG.&#xD;
&#xD;
          -  Subjects receiving daily treatment with nonsteroidal anti-inflammatory drugs (NSAIDs)&#xD;
             or cyclooxygenase-2 (COX-2) inhibitors that cannot be discontinued for the duration of&#xD;
             the study.&#xD;
&#xD;
          -  Concomitant oral or IV therapy with strong CY P3A inhibitors (ketoconazole,&#xD;
             itraconazole, voriconazole, telithromycin, clarithromycin, nefazodone, ritonavir,&#xD;
             saquinavir, nelfinavir, indinavir, atazana vir, grapefruit juice N1 L/d), CYP3A&#xD;
             substrates with narrow therapeutic indices (cyclosporine, quinidine), or strong CYP3A&#xD;
             inducers (rifampin/rifampicin, phenytoin, carbamazepine).&#xD;
&#xD;
          -  Increased risk of bradycardiac events.&#xD;
&#xD;
          -  Dialysis required.&#xD;
&#xD;
          -  Severe uncontrolled chronic obstructive pulmonary disease&#xD;
&#xD;
          -  Known severe hepatic impairment&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>95 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Dimitrios Alexopoulos, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University Hospital of Patras</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Cardiology Department Patras University Hospital</name>
      <address>
        <city>Rio</city>
        <state>Achaia</state>
        <zip>26500</zip>
        <country>Greece</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Greece</country>
  </location_countries>
  <verification_date>April 2013</verification_date>
  <study_first_submitted>April 9, 2012</study_first_submitted>
  <study_first_submitted_qc>April 10, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 11, 2012</study_first_posted>
  <last_update_submitted>April 9, 2013</last_update_submitted>
  <last_update_submitted_qc>April 9, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">April 10, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Patras</investigator_affiliation>
    <investigator_full_name>Dimitrios Alexopoulos</investigator_full_name>
    <investigator_title>Professor</investigator_title>
  </responsible_party>
  <keyword>Ticagrelor</keyword>
  <keyword>ST elevation acute myocardial infarction</keyword>
  <keyword>Platelet reactivity</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Myocardial Infarction</mesh_term>
    <mesh_term>ST Elevation Myocardial Infarction</mesh_term>
    <mesh_term>Infarction</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ticagrelor</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

